Direkt zum Inhalt
Merck

Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation.

PloS one (2014-08-29)
Laura Asnaghi, Michael H Lin, Kah Suan Lim, Kah Jing Lim, Arushi Tripathy, Murilo Wendeborn, Shannath L Merbs, James T Handa, Akrit Sodhi, Eli E Bar, Charles G Eberhart
ZUSAMMENFASSUNG

The transcriptional response promoted by hypoxia-inducible factors has been associated with metastatic spread of uveal melanoma. We found expression of hypoxia-inducible factor 1α (HIF-1α) protein in well-vascularized tumor regions as well as in four cell lines grown in normoxia, thus this pathway may be important even in well-oxygenated uveal melanoma cells. HIF-1α protein accumulation in normoxia was inhibited by rapamycin. As expected, hypoxia (1% pO2) further induced HIF-1α protein levels along with its target genes VEGF and LOX. Growth in hypoxia significantly increased cellular invasion of all 5 uveal melanoma lines tested, as did the introduction of an oxygen-insensitive HIF-1α mutant into Mel285 cells with low HIF-1α baseline levels. In contrast, HIF-1α knockdown using shRNA significantly decreased growth in hypoxia, and reduced by more than 50% tumor invasion in four lines with high HIF-1α baseline levels. Pharmacologic blockade of HIF-1α protein expression using digoxin dramatically suppressed cellular invasion both in normoxia and in hypoxia. We found that Notch pathway components, including Jag1-2 ligands, Hes1-Hey1 targets and the intracellular domain of Notch1, were increased in hypoxia, as well as the phosphorylation levels of Erk1-2 and Akt. Pharmacologic and genetic inhibition of Notch largely blocked the hypoxic induction of invasion as did the pharmacologic suppression of Erk1-2 activity. In addition, the increase in Erk1-2 and Akt phosphorylation by hypoxia was partially reduced by inhibiting Notch signaling. Our findings support the functional importance of HIF-1α signaling in promoting the invasive capacity of uveal melanoma cells in both hypoxia and normoxia, and suggest that pharmacologically targeting HIF-1α pathway directly or through blockade of Notch or Erk1-2 pathways can slow tumor spread.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Natriumorthovanadat, ≥90% (titration)
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
Natriumorthovanadat, 99.98% trace metals basis
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
Rapamycin, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Sigma-Aldrich
Rapamycin aus Streptomyces hygroscopicus, ≥95% (HPLC), powder
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Supelco
Rapamycin, VETRANAL®, analytical standard
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Supelco
Digoxin, analytical standard
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
USP
Digoxin, United States Pharmacopeia (USP) Reference Standard
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Digoxin, European Pharmacopoeia (EP) Reference Standard
Preise und Verfügbarkeit sind derzeit nicht verfügbar.
Digoxin für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Preise und Verfügbarkeit sind derzeit nicht verfügbar.